Campbell et al., MCL-1 is a prognostic indicator and drug target in breast cancer. (2018) Cell Death Dis. 16;9(2):19
Campbell and Tait. Targeting BCL-2 regulated apoptosis in cancer. (2018) Open Biol. 8(5): 180002.
Lee et al., MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
(2017) Cell Metabolism. 26:633-647.
Merino et al., Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. (2017) Science Translational Medicine. 2017;9(401) eaam7049.
Kotschy et al., The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. (2016) Nature 538(7626):477-82.